Lexeo positive Phase 1/2 data for LX2006 in FA cardio: LVMI -11.4% at 12mo, safe

Lexeo Therapeutics, Inc.

Mean LVMI reduction 11.4% at 12 months and 18.3% at 18 months in patients with elevated baseline LVMI.
75% of elevated-baseline patients achieved >10% LVMI reduction at 12 months.
hsTnI, a myocardial injury biomarker, reduced 53.3% on average at 12 months (n=5).
Frataxin expression increased post-treatment in all evaluable biopsies; no treatment-related SAEs.
Cohort 3 dosing started (1.2x10^12 vg/kg); DSMB endorsed progression; 13 total participants dosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.